You’re on our free ad-supported tier. Upgrade to NewsNow Essentials now and get your favourite news platform, faster, slicker and ads free.You’re on our free tier. Upgrade to NewsNow Essentials now. Faster, slicker and ads free.You’re on our free tier. Upgrade and go ads free now!

Home
Hot Topics
Australia
World
Sport
Business
Entertainment
Science
Technology
Lifestyle

Biogen
Biotech
Gilead Sciences
GM Food
Illumina
Topics

Advertisement

Biogen

Share

Top Latest Popular

AAIC26: Biogen stock drops after unveiling tau-targeting ASO data Clinical Trials Arena 14h

Clinical Trials Arena 14h

Biogen is paying $1 billion for a company that won't say what it makes. Here's why that's actually good news for BIIB investors. The Motley Fool 09:21 Sat, 04 Jul

The Motley Fool 09:21 Sat, 04 Jul

Biotechnology Pharma

Biogen: Key takeaways from needham’s meeting with top management Benzinga 16:34 Mon, 29 Jun

Benzinga 16:34 Mon, 29 Jun

Advertisement

Advertisement

Can Biogen's new drugs revive growth amid legacy sales slump? Zacks 14:29 Fri, 26 Jun

Zacks 14:29 Fri, 26 Jun

FDA clears at-home start dose for Alzheimer's drug Leqembi pharmaphorum 3d

pharmaphorum 3d

Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved PMLiVE 2d

PMLiVE 2d

Advertisement

Advertisement

Latest

In the last 8 hours

Biogen Taps Biopharmaceutical Veteran as Chief Legal Officer Bloomberg Law 16:38

Earlier Today

US biotech Biogen hires Spur Therapeutics CEO as next legal chief The Global Legal Post 11:20

AAIC26: Biogen stock drops after unveiling tau-targeting ASO data Clinical Trials Arena 09:54

Yesterday

Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data Zacks 17:02 Wed, 15 Jul

STAT Plus: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more STAT 14:10 Wed, 15 Jul

Biogen Appoints Michael J. Parini as Chief Legal Officer Biogen (Press Release) 13:23 Wed, 15 Jul

Biogen: Leqembi Real-World leader Study Shows Majority Of Early Alzheimer's Patients Remain Stable RTT News 08:55 Wed, 15 Jul

Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved PMLiVE 08:20 Wed, 15 Jul

Tuesday

New experimental Alzheimer’s drug shows potential after study shows slower cognitive decline Fortune 23:38 Tue, 14 Jul

Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi Zacks 18:24 Tue, 14 Jul

Advertisement

Advertisement

Advertisement

About our Biogen News

Biogen is an American multinational biotechnology company that specialises in treatment of neurological diseases.

NewsNow

Our Sites

NewsNow Nigeria

NewsNow România

NewsNow Australia

Work with us

Publisher Network

Dockside Online IDE

Legal

Subscription Terms

© Copyright 1997 - 2026 NewsNow Publishing Limited. All rights reserved.

Biotech Biotech
Back to Business Biotech
- GM Food GM Food
- AbbVie AbbVie
- Amgen Amgen
- Biogen Biogen
- BioNTech BioNTech
- Celltrion Celltrion
- Genentech Genentech
- Gilead Sciences
- Illumina Illumina
- Moderna Moderna